Mozobil

DRUG5 trials

Sponsors

University of Washington, University of Padova, Siddhartha Ganguly, IRCCS San Raffaele, Albert Einstein College of Medicine

Conditions

Beta-ThalassemiaBone MetastasesChronic Granulomatous Disease X-linked (X-CGD)DiabetesMultiple MyelomaOsteosarcoma

Phase 1

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

WithdrawnNCT03612466

Albert Einstein College of MedicineBone Metastases, Osteosarcoma

Start: 2022-08-31End: 2024-09-30Updated: 2022-10-14

Phase 2

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

CompletedNCT02703779

Siddhartha GangulyMultiple Myeloma

Start: 2016-03-31End: 2020-04-08Updated: 2021-06-18

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

RecruitingNCT03055247

IRCCS San RaffaeleChronic Granulomatous Disease X-linked (X-CGD)

Start: 2015-11-06End: 2026-07-18Target: 3Updated: 2025-09-18

Phase 4

Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

CompletedNCT02056210

University of PadovaDiabetes

Start: 2014-02-28End: 2014-10-31Target: 20Updated: 2014-10-24

Unknown Phase

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major

CompletedNCT01206075

University of WashingtonBeta-Thalassemia

Start: 2010-10-31End: 2014-12-31Updated: 2014-12-30

Related Papers

Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry.

2016-05-2010 citations